Approval given for SkyePharma’s asthma treatment – Stock Market Wire

Approval given for SkyePharma's asthma treatment
Stock Market Wire
StockMarketWire.com – SkyePharma (LSE SKP) has announced that the UK regulatory authority, the Medicines and Healthcare product Regulatory Agency (MHRA), has granted marketing authorisation for flutiform®, a combination product for the treatment of
SKYEPHARMA PLC : Half Yearly Report4-traders

all 4 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.